Form 4: Regeneron EVP Andrew Murphy Reports Stock Transactions
SEC Form 4
Andrew Murphy, EVP of Research at Regeneron Pharmaceuticals, reported the disposition of 1,054 shares of common stock to cover tax obligations, while also holding shares indirectly through a 401(k) plan.
Summary
- Andrew Murphy, the EVP of Research at Regeneron Pharmaceuticals, reported a transaction involving the company's common stock on December 16, 2024.
- He disposed of 1,054 shares at a price of $730.81 per share to satisfy tax obligations.
- Following the transaction, Murphy directly owns 49,074 shares of Regeneron common stock.
- He also indirectly owns 4,326 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document simply reports a stock transaction by an executive, likely for tax purposes. It doesn't indicate any significant positive or negative developments for the company.
Industry Context
Form 4 filings are routine disclosures required by the SEC for company insiders, providing transparency into their trading activities. This transaction appears to be related to tax obligations, which is a common occurrence.
Key Dates
| Date | Description |
|---|---|
| 12/16/2024 | Date of stock transaction (disposal of shares). |
| 12/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.